Hepatobiliary Malignancies: Molecular Insights, Clinical Challenges and Emerging Therapeutic Strategies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 8
Special Issue Editors
Interests: hepatocellular carcinoma; cholangiocarcinoma; gallbladder cancer; molecular markers; mutational profiles; response to systemic therapy
Interests: liver; pancreas; surgery; function
Special Issue Information
Dear Colleagues,
Primary hepatobiliary malignancies include hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. Optimal patient outcomes are achieved through multidisciplinary collaboration among medical, surgical, and radiation oncologists, as well as high-quality diagnostic and interventional radiologists. Owing to advances in next-generation sequencing, molecular vulnerabilities of hepatobiliary cancers are being unveiled, and novel regimens incorporating targeted agents and immunotherapy have achieved significant improvements in patient survival. Clinical hurdles that remain to be overcome include intratumoral heterogeneity and acquired resistance, underlying liver disease and hepatic decompensation, and predicting responses to various local therapies. Emerging therapeutic strategies include neoadjuvant therapy before surgery, utilization of circulating tumor DNA to guide diagnosis and treatment, and multiomics profiling, through which the promise of precision oncology is being realized.
Prof. Dr. Yun Shin Chun
Dr. Yoshikuni Kawaguchi
Dr. Martin Palavecino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- cholangiocarcinoma
- gallbladder cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
